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ABSTRACT
OBJECTIVES The aim of this study was to assess 1-year clinical outcomes among high-risk patients with failed surgical
mitral bioprostheses who underwent transseptal mitral valve-in-valve (MViV) with the SAPIEN 3 aortic transcatheter
heart valve (THV) in the MITRAL (Mitral Implantation of Transcatheter Valves) trial.
BACKGROUND The MITRAL trial is the first prospective study evaluating transseptal MViV with the SAPIEN 3 aortic
THV in high-risk patients with failed surgical mitral bioprostheses.
METHODS High-risk patients with symptomatic moderate to severe or severe mitral regurgitation (MR) or severe mitral
stenosis due to failed surgical mitral bioprostheses were prospectively enrolled. The primary safety endpoint was technical
success. The primary THV performance endpoint was absence of MR grade$2þ or mean mitral valve gradient$10 mmHg
(30 days and 1 year). Secondary endpoints included procedural success and all-cause mortality (30 days and 1 year).
RESULTS Thirty patients were enrolled between July 2016 and October 2017 (median age 77.5 years [interquartile
range (IQR): 70.3 to 82.8 years], 63.3% women, median Society of Thoracic Surgeons score 9.4% [IQR: 5.8% to 12.0%],
80% in New York Heart Association functional class III or IV). The technical success rate was 100%. The primary per-
formance endpoint in survivors was achieved in 96.6% (28 of 29) at 30 days and 82.8% (24 of 29) at 1 year. Thirty-day
all-cause mortality was 3.3% and was unchanged at 1 year. The only death was due to airway obstruction after swal-
lowing several pills simultaneously 29 days post-MViV. At 1-year follow-up, 89.3% of patients were in New York Heart
Association functional class I or II, the median mean mitral valve gradient was 6.6 mm Hg (interquartile range: 5.5 to
8.9 mm Hg), and all patients had MR grade #1þ.
CONCLUSIONS Transseptal MViV in high-risk patients was associated with 100% technical success, low procedural
complication rates, and very low mortality at 1 year. The vast majority of patients experienced significant
symptom alleviation, and THV performance remained stable at 1 year. (J Am Coll Cardiol Intv 2021;14:859–72)
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M ultiple studies have demon-strated that the risk for repeatmitral valve (MV) surgery is
high, with procedural mortality ranging be-
tween 6.3% and 15% (1–5). Third and fourth
redo mitral operations carry even higher mor-
tality risk of 17.3% and 40%, respectively (6).
A recent analysis of 11,973 patients from the
Society of Thoracic Surgeons (STS) database
revealed a 30-day mortality rate of 6.5% in
patients who underwent MV replacement
for the first time versus 11.1% in those who
underwent redo MV surgery (p < 0.0001) (7).
Transcatheter mitral valve replacement
(TMVR) using balloon-expandable aortic
transcatheter heart valves (THVs) has
emerged as an alternative to surgery for pa-
tients with severe MV disease due to degen-
erated bioprostheses or failed surgical
repairs with annuloplasty rings, as well as
native MV disease with severe mitral annular calcifi-
cation (MAC) in patients who are not good candidates
for conventional MV surgery. The VIVID (Valve-in-
Valve International Database) registry, the STS/
American College of Cardiology TVT (Transcatheter
Valve Therapy) Registry, and other registries
collected early outcomes of mitral valve-in-valve
(MViV) in high-risk patients (8–10). Transapical ac-
cess was used in the majority of procedures in the
initial experience using first- and second-generation
devices, but the use of transseptal access has
increased with the third-generation SAPIEN 3 valve
(Edwards Lifesciences, Irvine, California). Whether
outcomes could be improved with transeptal access
use was unknown until recently.
The MITRAL (Mitral Implantation of Transcatheter
Valves; IDE G140136; NCT02370511) trial is the first
prospective study to evaluate the safety and feasi-
bility of transseptal MViV using the third-generation
SAPIEN 3 valve in patients at high surgical risk. We
present herein the 1-year outcomes of transseptal
MViV in this trial.
METHODS
This study was conducted following ethical princi-
ples according to the Declaration of Helsinki as well
as U.S. Food and Drug Administration guidelines
(Code of Federal Regulations Title 21, Part 812) and
Good Clinical Practices recommended by the Inter-
national Organization for Standardization (ISO
14155:2011). The study was approved by the Mayo
Clinic Institutional Review Board and the respective
Institutional Review Boards of the participating in-
stitutions. All patients provided written informed
consent.
STUDY DESIGN. The MITRAL early feasibility study is
a physician-initiated, prospective, multicenter clin-
ical trial designed to evaluate the safety and feasi-
bility of TMVR using the SAPIEN XT and SAPIEN 3
valves. The study has 3 treatment arms, including
native MV disease with severe MAC treated with a
valve-in-MAC procedure, failing surgical repairs with
annuloplasty rings treated with mitral valve-in-ring,
and MViV in failed surgical bioprostheses. A total of
91 patients at high surgical risk were enrolled (valve-
in-MAC, n ¼ 31; mitral valve-in-ring, n ¼ 30; MViV,
n ¼ 30) and treated between March 2015 and
December 2017 at 13 sites in the United States. We
present herein the results of the MViV arm. Patients
were considered eligible for the study if they had
symptoms of New York Heart Association (NYHA)
functional class II or greater due to severe mitral
stenosis, defined as MV area <1.5 cm2 on trans-
thoracic echocardiography or at least moderate to
severe mitral regurgitation (MR). A list of inclusion
and exclusion criteria is provided in Supplemental
Appendix 1.
Candidates were presented in a live case-review
conference call to a subject eligibility committee
(including a cardiac surgeon, interventional cardiol-
ogists, an advanced cardiac imaging expert, and a
computed tomography core laboratory director) to
determine eligibility. Baseline echocardiographic and
computed tomographic (CT) studies were analyzed by
independent core laboratories. Clinical events were
adjudicated by an independent clinical events com-
mittee, and safety was monitored by a data and safety
monitoring board (Supplemental Appendix 2).
PROCEDURES. Transthoracic and transesophageal
echocardiograms were obtained according to pub-
lished guidelines and analyzed at an independent
core laboratory according to the American Society of
Echocardiography standard for echocardiography
SEE PAGE 873
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CT = computed tomographic
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LVOT = left ventricular outflow
tract
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NYHA = New York Heart
Association
STS = Society of Thoracic
Surgeons
THV = transcatheter heart
valve
TMVR = transcatheter mitral
valve replacement
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core laboratories (11,12). The cardiac CT image acqui-
sition protocol was similar to CT protocols for trans-
catheter aortic valve replacement (13), with
adjustments for MV analysis (14), summarized in
Supplemental Appendix 3 and illustrated in Figure 1.
Although the MViV software application was used in
the evaluation (15), the THV size was selected ac-
cording to the mitral neoannulus area (the inner area
of the surgical bioprosthetic ring) as determined by
cardiac CT analysis (Figure 1) (14). All patients were
treated with transseptal access and received intrave-
nous heparin during the procedure to maintain an
activated clotting time greater then 250 s. We have
previously published the technique of transseptal
MViV (14,16). The patients received single-
antiplatelet therapy indefinitely after MViV, and
anticoagulation was recommended for at least
3 months for patients who did not have indications
for long-term anticoagulation prior to TMVR.
OUTCOMES. The primary safety endpoint was tech-
nical success at exit from the cardiac catheterization
laboratory, defined as successful delivery and
retrieval of the transcatheter delivery system,
deployment of a single valve in the correct position in
the mitral annulus, adequate performance of the THV
with residual MR grade <2þ and mean MV gradient
(MVG) <10 mm Hg, no need for surgery or additional
reintervention, and patient exits the procedure room
alive. The primary THV performance endpoint was
absence of MR grade $2þ or mean MVG $10 mm Hg at
30 days and 1 year. Secondary safety endpoints
included procedural success and all-cause mortality
at 30 days and 1 year. Definitions and a complete list
FIGURE 1 Cardiac CT Analysis
Measurements of the mitral annulus made using 3mensio Structural Heart Workflow version 8.1 (Pie Medical Imaging, Maastricht, the Netherlands). (A) The mitral valve
“neoannulus” area of the surgical bioprosthesis measurement is shown from the surgeon’s short-axis view during diastole. (B) A 23-mm virtual SAPIEN 3 transcatheter
heart valve (THV) is placed in the mitral surgical bioprosthesis (pink); the size was selected according to neoannulus/surgical bioprosthesis area. (C) The virtual valve
placed in the mitral annulus is visualized in the left ventricular outflow tract (LVOT) long-axis view. The LVOT space is measured at the site where the THV stent frame
is in closest proximity of the septum (arrow). (D) Neo-LVOT area measurement shown in short-axis view during systole. After placing the virtual valve (pink), the
remaining LVOT area is measured (white). (E) Fluoroscopic simulation of transseptal access (arrow) for procedural planning purposes. (F) Fluoroscopic simulation of a
coplanar view of the mitral bioprosthesis representing the valve deployment angle to be used during mitral valve-in-valve implantation procedure.
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of secondary endpoints are provided in Supplemental
Appendix 4.
STATISTICAL ANALYSIS. Continuous variables are
expressed as median (interquartile range [IQR]).
Categorical variables are expressed as frequency
(percentage). Comparisons between time points were
made using a Wilcoxon test. Comparisons of median
mean MVG among THV sizes were made using
Kruskal-Wallis 1-way analysis of variance on ranks. A
Kaplan-Meier curve was generated for all-cause
mortality and for the composite endpoint of all-
cause mortality and hospitalization for heart failure.
For the purposes of this paper, all p values were 2
sided, and p values <0.05 were considered to indicate
statistical significant. All analyses were conducted
using R version 3.6.2 (R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
Between July 2016 and October 2017, 38 subjects were
screened and presented at a case-review conference
call for subject eligibility determination. Eight pa-
tients were excluded for the following reasons: severe
right ventricular dysfunction (n ¼ 3, considered to
have very poor prognosis because of severe right
ventricular dysfunction), hemodynamic instability
requiring intravenous pressors (n ¼ 2), lack of central
MR with mostly paravalvular regurgitation (n ¼ 1),
left ventricular ejection fraction <20% (n ¼ 1), and
risk for left ventricular outflow tract (LVOT) obstruc-
tion (n ¼ 1). Thirty patients were enrolled (the patient
flowchart is illustrated in Figure 2). Baseline clinical
characteristics, including the types of surgical valves
implanted, are presented in Table 1; median age was
77.5 years (IQR: 70.3 to 82.8 years), and 63.3% were
women. Multiple comorbidities were present,
including atrial fibrillation in 60%. The median STS
Predicted Risk of Mortality score for MV replacement
was 9.4% (IQR: 5.8% to 12.0%), and 80% of patients
were in NYHA functional class III or IV. Baseline
echocardiographic characteristics are listed in Table 2.
Median left ventricular ejection fraction was 56.2%
(IQR: 48.7% to 64.5%). Mitral stenosis was the pre-
dominant pathology, present in 73.3% of the subjects.
FIGURE 2 Patient Flowchart
CT ¼ computed tomographic; EF ¼ ejection fraction; LV ¼ left ventricular; LVOTO ¼ left ventricular outflow tract obstruction; MR ¼ mitral regurgitation;
PVL ¼ paravalvular leak.
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PROCEDURAL RESULTS AND PRIMARY SAFETY
ENDPOINT. All patients underwent transseptal MViV
with the SAPIEN 3 THV. Procedural results are pre-
sented in Table 3. The size of the THV was chosen
according to cardiac CT analysis, coinciding with the
size recommended by the MViV app in 63.3% of cases.
A different size than the one recommended by the
MViV app was chosen in 36.7% (1 size smaller in all).
The THV was prepared with additional contrast vol-
ume in the delivery system balloon catheter in 36.7%
of cases to flare the THV in the left ventricle to
decrease the risk for valve embolization to the left
atrium and to optimize valve performance. The pri-
mary safety endpoint of technical success at exit from
the procedure room was achieved in 100% of patients.
There were no cases of LVOT obstruction, need for a
second THV during index procedure, intraprocedural
mortality, or conversion to open heart surgery. Atrial
septostomy was closed percutaneously in 1 patient
during the index procedure (3.3%), at the discretion
of the operator.
ADDITIONAL ENDPOINTS. The primary THV perfor-
mance endpoint of absence of MR grade 2þ or greater
or mean MVG $10 mm Hg was achieved in 96.6% of
survivors at 30 days (28 of 29) and in 82.8% of pa-
tients alive at 1 year (24 to 29). The reason for not
meeting the performance endpoint at 30 days or 1
year was a mean MVG $10 mm Hg in all 5 patients (3
treated with the 26-mm and 2 with the 29-mm SAPIEN
3). One of those 5 patients was treated with a size
smaller than recommended by the MViV app (a 27-
mm Magna, which has a true internal diameter of
26 mm, and developed a stenosis that was treated
with a 26-mm THV instead of a 29-mm THV), and the
remaining were treated with THV sizes recommended
by the MViV app. The secondary safety endpoint of
procedural success was achieved in 93.3% (28 of 30).
Reasons for not achieving procedural success in 2
subjects included 1 death and a mean MVG of
10.4 mm Hg at 30 days in 1 subject. All-cause mor-
tality at 30 days was 3.3% and remained unchanged at
1 year (Kaplan-Meier survival curves are presented in
Figure 3 and the Central Illustration).
TABLE 2 Baseline Echocardiographic Characteristics (n ¼ 30)
Ejection fraction (%) 56.2 (48.7–64.5)
Stroke volume (ml) 59.4 (43.5–77.5)
Cardiac output (l/min) 3.3 (1.6–4.6)
Mean MVG (mm Hg) 11.1 (7.4–13.7)
MVA (cm2) 1.4 (1.2–1.8)
Pulmonary artery systolic pressure (mm Hg) 40.1 (32.8–54.0)
Peak LVOT gradient (mm Hg) 4.1 (3.0–5.9)
Mean LVOT gradient (mm Hg) 2.0 (1.3–2.6)
Predominant pathology (mode of bioprosthesis failure)
Stenosis 22 (73.3)
Regurgitation 3 (10)
Both stenosis and regurgitation 5 (16.7)
Severity of mitral regurgitation





Values are median (interquartile range) or n/N (%).
LVOT ¼ left ventricular outflow tract; MVA ¼ mitral valve area; MVG ¼ mitral valve gradient.
TABLE 1 Baseline Patient Characteristics (n ¼ 30)
Age (yrs) 77.5 (70.3–82.8)
Female 19/30 (63.3)
Diabetes 6/30 (20)
Atrial fibrillation 18/30 (60)
Chronic kidney disease 6/30 (20)
Chronic obstructive pulmonary disease 6/30 (20)
Home oxygen therapy 3/30 (10)
Receiving long-term anticoagulation 17/30 (56.7)
Hospitalization for heart failure during prior
12 months
14/30 (46.7)
Prior stroke 4/30 (13.3)
Prior CABG 11/30 (36.7)
Prior AVR 6/30 (20)
TAVR 2 (33.3)
SAVR 4 (66.7)
Type of surgical bioprosthesis
Edwards Perimount (Perimount, Magna Ease,
Baxter)
16/30 (53.3)
Medtronic Mosaic 6/30 (20)
S. Jude Biocor/Epic 5/30 (16.7)
Edwards CE Standard 3/30 (10)






Values are median (interquartile range) or n/N (%).
AVR ¼ aortic valve replacement; CABG ¼ coronary artery bypass grafting;
MVR ¼ mitral valve replacement; NYHA ¼ New York Heart Association;
SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgeons;
TAVR ¼ transcatheter aortic valve replacement.
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30-DAY OUTCOMES. At 30-day follow-up, 96.7% of
patients (29 of 30) were alive, and 82.8% were in New
York Heart Association functional class I or II. The
single death observed within 30 days occurred on day
29 post-MViV, due to asphyxia when the patient
swallowed 6 pills at the same time at home. This was
confirmed by autopsy and was adjudicated as non-
cardiovascular death. Clinical events at 30 days and 1
year are presented in Table 4 and echocardiographic
characteristics in Table 5. One patient had sponta-
neous intracranial microhemorrhage within 30 days
found on brain magnetic resonance imaging done for
headache (with no focal deficit per a neurologist’s
evaluation). No patient required MV reintervention.
There were no THV thrombosis, hemolysis, or THV
endocarditis events.
1-YEAR OUTCOMES. At 1-year follow-up (median 1.1
years; IQR: 1.0 to 1.9 years), 96.7% of patients (29 of
30) were alive, and 89.3% were in NYHA functional
class I or II. There were no deaths after 30-day follow-
up (Table 4). A descriptive summary of each patient,
including essential baseline characteristics and out-
comes, is provided in Table 6. A total of 5 patients had
rehospitalization for heart failure (16.7%), 1 within
30 days because of decompensated diastolic heart
failure and 4 after 30 days (2 because of acute on
chronic diastolic heart failure, 1 because of pre-
existing underlying systolic heart failure, and 1 with
suspected contribution from a left-to-right shunt who
underwent percutaneous closure of the iatrogenic
interatrial septal defect). Three of these patients met
the THV performance endpoint at 1 year, and 2 did
not because of mean MVG $10 mm Hg (11.6 and
14.7 mm Hg at heart rates of 90 and 81 beats/min,
respectively; heart rate unchanged from baseline).
Two patients underwent septostomy closure after
30 days because of left-to-right shunt and suspected
right ventricular overload. Additional adverse events
were rare. One patient had an intracranial hemor-
rhage after 30 days subsequent to trauma after a fall.
There were no late THV migration or embolization
events, endocarditis, or THV thrombosis (systemati-
cally searched for using transthoracic echocardiogra-
phy). No hemolytic anemia events were detected with
routine biological markers, including haptoglobin and
plasma free hemoglobin levels. Patients who were
alive at 1 year experienced significant improvement
in NYHA functional class (Figure 4), improvement in
6-min walk distance (Figure 5), and improvement in
quality-of-life scores (Figure 6). Most patients
continued oral anticoagulation (Figure 7). Left ven-
tricular function remained unchanged. TMVR device
function remained stable, with a median mean MVG
of 6.6 mm Hg (IQR: 5.5 to 8.9 mm Hg) in the entire
cohort, but mean MVG was greater for the smaller 23-
mm THVs (8.4 mm Hg [IQR: 7.3 to 9.6 mm Hg] vs.
6.0 mm Hg [IQR: 5.0 to 7.7 mm Hg] for the 29-mm
TABLE 3 Intraprocedural Results (n ¼ 30)
Device
SAPIEN 3 30/30 (100)
Device size
23 mm 4/30 (13.3)
26 mm 13/30 (43.3)




Additional contrast during initial deployment
No 19/30 (63.3)
Yes 11/30 (36.7)
Amount (ml) 0.0 (0.0–3.0)
Post-dilatation 4/30 (13.3)
Septostomy closed 1/30 (3.3)
Results
In-hospital mortality 1/30 (3.3)
Cardiovascular 0
Noncardiovascular 1/30 (3.3)
Technical success at exit from catheterization laboratory 30/30 (100)
LVOT obstruction with hemodynamic compromise 0 ()
Need for a second valve 0 ()
$2þ MR on procedural TEE 0 ()
Paravalvular leak closure during index procedure 0 ()
Vascular complications 0/30 (0)
Conversion to open heart surgery 0 ()
Valve embolization 0 ()
Left ventricular perforation 0 ()
Pericardial effusion requiring pericardiocentesis 0 ()
New pacemaker requirement 1/30 (3.3)
Myocardial infarction requiring intervention 0 ()
Echocardiographic characteristics post-TMVR
Mean MVG (mm Hg) 2.9 (2.0–3.9)
Peak LVOT gradient (mm Hg)† 5.4 (3.9–8.9)
Mean LVOT gradient (mm Hg)† 2.5 (2.0–4.4)
Residual total MR at end of procedure




Amount of paravalvular MR at end of procedure




Values are n/N (%) or median (interquartile range). *Performed in patients with very severe mitral
stenosis to avoid hemodynamic decompensation during valve positioning and deployment. †Eight
missing values.
MR ¼ mitral regurgitation; TEE ¼ transesophageal echocardiogram; TMVR ¼ transcatheter
mitral valve replacement; other abbreviations as in Tables 1 and 2.
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THV) (Figure 8). All patients had grade 1þ or less total
MR at 1 year.
DISCUSSION
This is the first prospective, multicenter, U.S. Food
and Drug Administration–approved early feasibility
clinical trial with independent imaging core labora-
tories and independent clinical event adjudication to
evaluate the safety and feasibility of transseptal MViV
using the SAPIEN 3 balloon-expandable aortic THV.
The main findings of this study are as follows: 1)
Transseptal MViV in selected patients at high surgical
risk was associated with a 100% technical success
rate, a low procedural complication rate, and a low
mortality rate (3.3%) at 1 year in a patient population
with a median STS score of 9.4%; 2) transseptal MViV
was associated with alleviation of symptoms,
improvement in 6-min walk distance, and improve-
ment in quality-of-life scores; and 3) the performance
of the THV was acceptable and remained stable at 1
year.
The findings of this trial are different from those
of prior published studies that evaluated the early
experience of MViV procedures. In those early re-
ports of retrospective studies, procedure-related
complications and mortality rates were higher than
in this prospective study. The initial 30-day all-cause
mortality rate in the VIVID registry was 7.7% in a
patient population with an STS score of 13.4% (8).
Similarly, the initial 30-day mortality rate in the TVT
Registry was 8.1% in patients with an STS score of
10% (10). The VIVID registry and initial analysis of
the TVT Registry included patients treated with first-
and second-generation devices, and a large propor-
tion of patients were treated via transapical access
(64.4% and 46.8%, respectively) (10,17). A subse-
quent multicenter retrospective registry study of 60
MViV patients all treated with a transseptal
approach demonstrated better outcomes, with a 30-
day mortality rate of 5% and a procedural success
rate of 97% (9). Two additional contemporary retro-
spective registries reported similar 30-day mortality
rates of 5.9% and 6.2%, with all-cause mortality rates
at 1 year of 13.2% and 23.5%, respectively (18,19).
The all-cause 1 year mortality rate of 3.3% in our
study was significantly lower than those in the
earlier studies.
FIGURE 3 Kaplan-Meier Survival Curves
HF ¼ heart failure; KM ¼ Kaplan-Meier; ViV ¼ valve-in-valve.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 4 , N O . 8 , 2 0 2 1 Guerrero et al.
A P R I L 2 6 , 2 0 2 1 : 8 5 9 – 7 2 MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes
865
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by 
Elsevier on May 06, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.
The patient populations in prior studies were
heterogenous, with different delivery access routes
and valve types used. A difference in outcomes
related to type of delivery access (transapical vs.
transseptal) was not demonstrated until recently. A
contemporary analysis of the TVT Registry including
only patients treated with the SAPIEN 3 valve found a
30-day mortality rate of 8.1% in patients treated with
transapical MViV versus 5.0% in patients treated with
transseptal access (p ¼ 0.07). The difference in mor-
tality was even more pronounced at 1 year (21.7% with
transapical access vs. 15.7% with transseptal access;
p ¼ 0.03) (20).
With 100% transseptal access and careful patient
selection in the present study, the investigators were
able to reduce the mortality rate to 3.3% at 1 year. The
only death was noncardiovascular (asphyxia after
taking 6 pills simultaneously on day 29 post-MViV).
The very low mortality at 1 year in our study is
equivalent to one-fifth of the 15.7% mortality rate
observed in the TVT Registry with transseptal MViV,
suggesting significant progress in this field. In addi-
tion, technical success in this study was 100%. There
were no intraprocedural deaths, need for a second
valve, THV device embolization, LVOT obstruction, or
conversion to open heart surgery during the index
procedure. We attribute the improved outcomes in
this study to careful patient selection, including car-
diac CT analysis in all patients to identify patients at
risk for complications such as LVOT obstruction.
CENTRAL ILLUSTRATION 30-Day and 1-Year Outcomes of Mitral Valve-in-Valve in the Mitral Implantation of
Transcatheter Valves Trial
Guerrero, M. et al. J Am Coll Cardiol Intv. 2021;14(8):859–72.
Early and late outcomes for functional capacity (New York Heart Association functional class; left) and 6-min walk distance (right; median and interquartile range).
Both measures were significantly improved compared with baseline and remained stable. The early mortality (depicted as Kaplan-Meier survival; center) was better
than expected on the basis of the Society of Thoracic Surgeons score.
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Another factor that may have contributed to
improved outcomes is the experience of the operators
participating in this trial. We have previously
described the technique used (14,16). Ongoing edu-
cation and proctoring of new operators during these
procedures may allow the overall outcomes to
continue to improve in the real-world experience
outside the confines of a clinical trial.
REPEAT MITRAL SURGERY VERSUS MViV. An anal-
ysis from the STS database including 11,973 patients
showed that 30-day mortality among patients un-
dergoing redo MV surgery was higher (11.1%) than
among patients who underwent first-time mitral
surgery (6.5%) (7). However, there are no data from
randomized prospective studies comparing outcomes
of patients who undergo repeat MV surgery versus
MViV. Limited data exist from small retrospective
studies that have demonstrated no significant differ-
ence in mortality between these approaches. In a
retrospective study, Kamioka et al. (21) compared 62
patients who underwent MViV (STS score 12.7%, 48
transseptal and 14 transapical) with 59 patients
treated with repeat surgery (STS score 8.7%) and
found 1-year mortality rates of 11.3% versus 11.9%,
respectively (p ¼ 0.92). In a similar study, Simonetto
et al. (22) compared the outcomes of 29 patients who
underwent redo MV surgery (STS score 3.6%) and 49
patients who underwent MViV (27 transseptal [STS
score 8.5%] and 22 transapical [STS score 8.9%]) and
found no significant difference in mortality at 1 year
(17.2%, 14.8%, and 18.2%; p ¼ 1.00).
It is unlikely that a randomized study evaluating
transseptal MViV in high-risk patients will be con-
ducted considering the low mortality rate observed in
our study. The Food and Drug Administration has
already approved MViV for high-risk patients. How-
ever, a prospective study evaluating intermediate-
risk patients is already ongoing (PARTNER [Place-
ment of Aortic Transcatheter Valve] 3 Trial – Mitral
Valve in Valve; NCT03193801).
THV PERFORMANCE. The primary THV performance
endpoint of absence of MR grade $2þ or mean
MVG $10 mm Hg was achieved in 96.6% of patients
alive with echocardiographic data available at 30 days
(28 of 29) and 82.8% at 1 year (24 of 29). Five patients
did not meet the performance endpoint at 1 year, and
the reason was a mean MVG >10 mm Hg. Three of
those were treated with 26-mm and 2 with 29-mm
SAPIEN 3 THVs (3 had mitral stenosis as predomi-
nant mode of failure at baseline, 1 had MR, and 1 had
mixed pathology at baseline). Importantly, 80% of
these patients had alleviation of symptoms despite
high residual gradients and were in NYHA functional





All-cause mortality 1/30 (3.3) 1/30 (3.3)
Cardiovascular 0/30 (0) 0/30 (0)
Noncardiovascular 1/30 (3.3) 1/30 (3.3)
Device success 28/30 (93.3) Not applicable
Procedural success 28/30 (93.3) Not applicable
Primary performance endpoint in survivors 28/29* (96.6) 24/29* (82.8)
Stroke 1/30 (3.3) 2/30 (6.7)
Ischemic 0/30 (0) 0/30 (0)
Hemorrhagic† 1/30 (3.3) 2/30 (6.7)
Myocardial infarction requiring revascularization 0/30 (0) 0/30 (0)
Mitral valve reintervention after index procedure 0/30 (0) 0/30 (0)
Septostomy closed‡ 1/30 (3.3) 3/30 (10)
Acute kidney injury requiring hemodialysis 0/30 (0) 0/30 (0)
Blood transfusion 3/30 (10) 6/30 (20)
Major vascular complication§ 1/30 (3.3) 1/30 (3.3)
New permanent pacemaker requirement 1/30 (3.3) 1/30 (3.3)
New-onset atrial fibrillation 0/30 (0) 0 (0)
New hospitalization for heart failure 1/30 (3.3) 5/30 (16.7)
Device embolization or migration 0/30 (0) 0/30 (0)
Hemolytic anemia 0/30 (0) 0/30 (0)
Valve thrombosis 0/30 (0) 0/30 (0)
Endocarditis 0/30 (0) 0/30 (0)
New York Heart Association functional class||
I 14/29 (48.3) 10/28 (35.7)
II 10/29 (34.5) 15/28 (53.6)
III 5/29 (17.2) 3/28 (10.7)
IV 0/29 (0) 0/28 (0)
Values are n/N (%). *1 patient died on day 29 after transcatheter mitral valve replacement. †1 spontaneous
intracranial microhemorrhage found on magnetic resonance imaging done for headache (no focal deficit per
neurologist’s evaluation) and 1 hemorrhage after a fall. ‡11 during index procedure and 2 between 30-day and
1-year follow-up. §Pulmonary embolism on post-operative day 2. ||1 died and one subject missing New York Heart
Association functional class at 1 year.
TABLE 5 Echocardiographic Characteristics at 30 Days and 1 Year
30 Days (n ¼ 29*) 1 Year (n ¼ 29*)
Ejection fraction (%) 56.6 (47.0–66.2) 57.7 (45.8–62.3)
Stroke volume (ml) 54.0 (45.0–69.0) 65.6 (52.6–79.3)†
Cardiac output (l/min) 3.1 (1.7–4.3) 4.6 (3.7–5.2)†
Mean MVG (mm Hg) 6.0 (4.7–7.3) 6.6 (5.5–8.9)
Pulmonary artery systolic pressure (mm Hg) 32.2 (27.8–39.0) 45.3 (35.8–54.8)
Peak LVOT gradient (mm Hg) 4.9 (4.0–8.0) 4.1 (2.6–6.8)
Mean LVOT gradient (mm Hg) 2.9 (1.8–4.5) 2.4 (1.5–3.9)
Severity of total mitral regurgitation
None to trace 28/29 (96.6) 26/29 (89.6)
1þ 1/29 (3.4) 3/29 (3.4)
2þ 0/29 (0) 0/29 (0)
$3þ 0/29 (0) 0/29 (0)
Severity of paravalvular mitral regurgitation
None to trace 29/29 (100.0) 27/29 (93.1)
1þ 0/29 (0.0) 2/29 (6.9)
2þ 0/29 (0) 0/29 (0)
$3þ 0/29 (0) 0/29 (0)
Values are median (interquartile range) or n/N (%). *1 died on post-operative day 29. †15 missing values.
Abbreviations as in Table 2.
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class I or II at 1 year. Only 1 patient remained in NYHA
functional class III at 1 year.
Although the mean MVG in the entire cohort was
higher than reported for THVs designed for the mitral
position (7.3  2.7 mm Hg vs. 3.0  1.1 mm Hg) (23), it
was similar to the gradients observed at 1 year in the
VIVID registry (6.7  2.7 mm Hg) (17) and the TVT
Registry (7.0  2.94 mm Hg) (20). The mechanism for
mitral higher gradients has not been elucidated.
Factors contributing may include restricted expan-
sion limited by the surgical prosthesis, undersizing,
and thrombosis. However, thrombosis was not
observed by the echocardiography core laboratory in
these patients. Nevertheless, routine transesophageal
echocardiographic or cardiac CT imaging was not
performed at 1-year follow-up, which could have
helped confirm the presence or absence of valve
thrombosis. Valve fracture using a high-pressure
balloon to optimize gradients during the index pro-
cedure has been reported (24). However, valve frac-
ture was not used in this study, because of limited
data and lack of high mitral gradients observed on



















1 F 69 Perimount 6900 25 MS 26 391.5 23
2 M 67 Mosaic 29 MS 26/29 480 26
3 M 77 Mosaic 29 MR 26/29 581 29
4 F 84 Biocor 29 MS 29 510 29
5 F 64 Epic 27 MS 26 443.5 26
6 M 75 Perimount 6900 33 MS 29/NA 586.5 29
7 F 82 Perimount 6900 27 MS 29 453 26
8 M 96 Biocor 29 MR 29 538.5 26
9 M 78 Mosaic 31 MR 29 680 29
10 M 58 Baxter (Edwards) 31 MS 29/NA 635 29
11 F 88 Mosaic 31 MR 29 655.5 29
12 M 73 Perimount 31 Mixed 29 620 29
13 F 82 Perimount 27 MS 29 486 26
14 F 75 Perimount 25 Mixed 26 415 23
15 F 89 Perimount 27 MS 29 476 26
16 F 85 Epic 31 MS 29 605.5 29
17 F 53 Perimount 31 MS 29/NA 587.5 29
18 F 78 Epic 29 MR 29 500 26
19 F 78 Perimount 25 MS 26 392 23
20 M 75 Perimount 25 MS 26 400 26
21 F 86 Mosaic 27 MR 26 480 26
22 F 83 Perimount 25 MS 26 406.5 23
23 F 76 Perimount 25 MS 26 408.5 26
24 M 81 CE Standard 31 MR 29 640 29
25 M 66 CE Standard 33 Mixed 29/NA 678 29
26 M 81 CE Standard 33 Mixed 29/NA 660 29
27 F 87 Perimount 31 MS 29/NA 657 29
28 F 70 Mosaic 27 MR 26 417.5 26
29 F 71 Magna Ease 27 MS 29 500.5 26
30 F 65 Perimount 27 MS 29 480 26
*Patient died on day 29 post-MViV from asphyxia after taking 6 pills together.
CT ¼ computed tomography; MR ¼ mitral regurgitation; MS ¼ mitral stenosis; MVG ¼ mitral valve gradient; MViV ¼ mitral valve-in-valve; NA ¼ not applicable; THV ¼ transcatheter heart valve.
Continued on the next page
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transesophageal echocardiography immediately after
MViV deployment. The long-term significance of the
high residual mitral gradients in these patients is not
known. This prospective trial may provide further
insights about this finding.
STUDY LIMITATIONS. First, this was an early feasi-
bility study with a small number of patients enrolled.
Because the trial design was not randomized and
controlled, the results cannot provide evidence that
MViV in high-risk patients with failed surgical bio-
prostheses is superior to repeat standard MV surgery.
The patient population as well as the operators in this
study were highly selected. Therefore, the results
cannot be applied to the general population. The
residual MVGs after MViV appeared to be higher than
gradients after surgical MV replacement or TMVR
with dedicated mitral THVs used for native MV
replacement. The long-term significance of this
finding is unknown. Follow-up cardiac CT imaging
was not performed at 1 year; long-term follow-up CT
analysis could have helped identify the mechanism of
higher mitral gradients.
NEXT STEPS. Further studies are needed to evaluate
the outcomes of MViV in lower surgical risk patients.
The PARTNER 3 Trial – Mitral Valve in Valve is a
multicenter prospective registry evaluating the safety
















Endpoint Met at 1 Year
Yes No Yes Yes Yes Yes Yes
Yes No Yes No (mean MVG >10 mm Hg) No (mean MVG >10 mm Hg) Yes Yes
Yes No Yes Yes Yes Yes No (MVG >10 mm Hg)
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes No (MVG >10 mm Hg)
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No No* No* No (not available)* No* No*
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes No (MVG >10 mm Hg)
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes No (MVG >10 mm Hg)
Yes No Yes Yes Yes Yes Yes
No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes Yes
Yes No Yes Yes Yes Yes No (MVG >10 mm Hg)
Yes No Yes Yes Yes Yes Yes
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CONCLUSIONS
Transseptal MViV in high-risk patients was associated
with 100% technical success, low procedural compli-
cation rates, and very low mortality at 1 year. Most
patients experienced significant alleviation of symp-
toms, and THV performance remained stable at 1
year. Transseptal MViV may be considered the stan-
dard of care for high-risk patients with degenerated
mitral bioprostheses who have favorable anatomy
pending longer term results.
FIGURE 6 Quality-of-Life Scores
IQR ¼ interquartile range; KCCQ ¼ Kansas City Cardiomyopathy
Questionnaire.
FIGURE 7 Percentage of Patients Receiving Oral
Anticoagulation
ViV ¼ valve-in-valve.
FIGURE 4 NYHA Functional Class
NYHA ¼ New York Heart Association.
FIGURE 5 6-Min Walk Test
IQR ¼ interquartile range.
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PERSPECTIVES
WHAT IS KNOWN? Patients with failed mitral bioprostheses
who need repeat MV surgery often have high surgical risk.
WHAT IS NEW? Transseptal MViV in high-risk patients was
associated with 100% technical success, low procedural
complication rates, and very low all-cause mortality at 1 year.
WHAT IS NEXT? Further studies are needed to confirm the
safety and efficacy of MViV in lower risk patients and to evaluate
the durability of THV performance.
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APPENDIX For inclusion and exclusion
criteria, MITRAL trial valve-in-valve arm trial
operations, supplemental methods (cardiac
computed tomography), study endpoints, and
supplemental references, please see the online
version of this paper.
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